Lumena Pharmaceuticals Report issue

For profit Phase 2
Founded: San Diego CA United States (2011)
Status: Acquired by Shire (2014) → now Takeda (2018)

Organization Overview

First Clinical Trial
2013
NCT02047318
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Lumena Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

maralixibat (LIVMARLI) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alagille Syndrome (Phase 2)

Liver Diseases (Phase 2)

Substance Withdrawal Syndrome (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1